TAMPA, Fla., Dec. 15, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...
IGM Biosciences, Inc. has announced a definitive merger agreement with Concentra Biosciences, LLC, under which Concentra will acquire IGM for $1.247 in cash per share of common stock, along with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback